Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules

Int J Cancer. 1998 Jul 17;77(2):181-7. doi: 10.1002/(sici)1097-0215(19980717)77:2<181::aid-ijc2>;2-m.


Adhesion and accessory molecules play a critical role in T-cell activation and effector function in general and in tumor cell recognition and lysis in particular. We investigated the contribution of CD2, CD3, CD11a/CD18, CD54 and CD58 molecules in T lymphocyte-tumor cell interactions mediated by chimeric immunoglobulin receptors. The chimeric receptor is composed of a single chain antibody binding site and a gamma-chain signal transducing molecule (scFv/gamma). T lymphocytes expressing such scFv/gamma receptors recognize the G250 Ag on renal cell carcinoma (RCC) in an major histocompatibility complex (MHC)-unrestricted manner and exert RCC selective cytolysis. A coregulatory role for CD2, CD3 and CD11a/CD18 molecules in scFv/gamma-mediated cytolysis was demonstrated using monoclonal antibody (MAb)-induced inhibition of scFv/gamma-mediated cytolysis. The inhibition of lysis was not due to inhibition of cytotoxic T lymphocyte (CTL)-target cell conjugation but rather to a post-conjugate signaling event. Binding of CD54 and CD58 MAbs to the RCC did not inhibit cytolysis of RCC cells that expressed high levels of both CD54 and the G250 antigen (Ag) (A75), whereas cytolysis of RCC expressing intermediate levels of CD54 and G250 Ag (SK-RC-17 cl.4) was partly inhibited by the CD54 MAb. Binding of low concentrations of G250 MAb to RCC (A75) rendered these cells sensitive to CD54 MAb inhibition, demonstrating a direct functional relation between G250 Ag expression level and adhesion molecules. Taken together, our findings indicate a coregulatory role for CD2, CD3 and CD11a/CD18 molecules in the scFv/gamma-mediated cytolysis of tumor cells and show that the requirement of CD11a/CD18-CD54 interactions is dependent on the level of free Ag. This make these gene-transduced T lymphocytes attractive tools for adoptive immunogene therapy of cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antigens, CD / immunology*
  • Antigens, Neoplasm / immunology*
  • CD11 Antigens / immunology
  • CD18 Antigens / immunology
  • CD2 Antigens / immunology
  • CD3 Complex / immunology
  • CD58 Antigens / immunology
  • Carcinoma, Renal Cell / immunology*
  • Cytotoxicity, Immunologic
  • Humans
  • Immunoglobulin Fragments / immunology*
  • Intercellular Adhesion Molecule-1 / immunology
  • Melanoma / immunology
  • Receptors, Antigen, T-Cell, gamma-delta / immunology*
  • Recombinant Fusion Proteins / immunology*
  • T-Lymphocytes, Cytotoxic / immunology*
  • Transfection
  • Tumor Cells, Cultured


  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, Neoplasm
  • CD11 Antigens
  • CD18 Antigens
  • CD2 Antigens
  • CD3 Complex
  • CD58 Antigens
  • Immunoglobulin Fragments
  • Receptors, Antigen, T-Cell, gamma-delta
  • Recombinant Fusion Proteins
  • Intercellular Adhesion Molecule-1